QUANTA Lite Calprotectin is a quantitative enzyme linked immunosorbent assay (ELISA) to detect calprotectin levels.

The new FDA-cleared assay will also differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other laboratory and clinical findings.

INOVA Diagnostics Research and Development Vice President Michael Mahler said the high performing assay will meet the increasing demand from laboratories worldwide.

"Gastrointestinal pain is a common reason for seeking medical attention. Inaccurate diagnosis at the screening level can contribute to unnecessary procedures and increased healthcare costs," Mahler added.

"The QUANTA Lite Calprotectin assay can improve patient care while potentially reducing overall costs."

The accurate detection of calprotectin levels in stool can provide critical information to physicians determining the appropriate care of millions of patients suffering from gastrointestinal disorders, according to the company.

INOVA Diagnostics CEO Roger Inglès said, "The benefits of fecal calprotectin testing are being recognized by healthcare systems around the world as evidenced by the recent recommendation from the National Institute for Health and Care Excellence (NICE) in the UK."